Laquinimod - Teva Pharmaceutical Industries

Drug Profile

Laquinimod - Teva Pharmaceutical Industries

Alternative Names: ABR-215062; Laquinimod sodium; Nerventra; SAIK-MS; TV-5600

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Active Biotech
  • Developer Icahn School of Medicine at Mount Sinai; National University of Singapore; Ruhr-University Bochum; Tel Aviv University; Teva Pharmaceutical Industries; University College London; University of British Columbia
  • Class Anti-inflammatories; Neuropsychotherapeutics; Quinolones; Small molecules
  • Mechanism of Action Aryl hydrocarbon receptor agonists; Brain-derived neurotrophic factor expression stimulants; Immunomodulators; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Multiple sclerosis
  • Phase II Crohn's disease; Huntington's disease
  • No development reported Lupus nephritis
  • Discontinued Systemic lupus erythematosus

Most Recent Events

  • 08 Feb 2018 Teva and Active Biotech completes the phase II ARPEGGIO trial in Primary progressive multiple sclerosis (PPMS) in USA, United Kingdom, Spain, Ukraine, Italy, Canada, Germany, Netherlands, Poland and Russia (PO) (NCT02284568)
  • 01 Dec 2017 Efficacy and adverse event data from the phase II ARPEGGIO trial in Multiple sclerosis, which did not meet its primary endpoint, released by Active Biotech (NCT02284568)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Huntington's-disease in Israel (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top